WO2013027146A1 - The method of obtaining a strain of bacteriofage, specific strains of bacteriophage and use thereof - Google Patents

The method of obtaining a strain of bacteriofage, specific strains of bacteriophage and use thereof Download PDF

Info

Publication number
WO2013027146A1
WO2013027146A1 PCT/IB2012/054070 IB2012054070W WO2013027146A1 WO 2013027146 A1 WO2013027146 A1 WO 2013027146A1 IB 2012054070 W IB2012054070 W IB 2012054070W WO 2013027146 A1 WO2013027146 A1 WO 2013027146A1
Authority
WO
WIPO (PCT)
Prior art keywords
strain
bacteriophage
culture
salmonella
bacteria
Prior art date
Application number
PCT/IB2012/054070
Other languages
French (fr)
Inventor
Jarosław DASTYCH
Jarosław DZIADEK
Elżbieta FORNAL
Jarosław RUMIJOWSKA-GALEWICZ
Arkadiusz WOJTASIK
Ewelina WÓJCIK
Original Assignee
Proteon Pharmaceuticals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proteon Pharmaceuticals S.A. filed Critical Proteon Pharmaceuticals S.A.
Priority to US14/240,195 priority Critical patent/US9476086B2/en
Priority to RU2014111125/10A priority patent/RU2573934C2/en
Priority to EP12770231.4A priority patent/EP2747578B1/en
Priority to ES12770231T priority patent/ES2710429T3/en
Priority to UAA201403018A priority patent/UA112551C2/en
Publication of WO2013027146A1 publication Critical patent/WO2013027146A1/en
Priority to US15/297,587 priority patent/US9999237B2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K10/00Animal feeding-stuffs
    • A23K10/10Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K50/00Feeding-stuffs specially adapted for particular animals
    • A23K50/70Feeding-stuffs specially adapted for particular animals for birds
    • A23K50/75Feeding-stuffs specially adapted for particular animals for birds for poultry
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18Testing for antimicrobial activity of a material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00Bacteriophages
    • C12N2795/00011Details
    • C12N2795/00021Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00Bacteriophages
    • C12N2795/00011Details
    • C12N2795/00032Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Definitions

  • This invention relates to a method for preparing a strain of bacteriophage specific to a selected strain of bacteria, bacteriophage strains obtained in this way and the application of bacteriophages to manufacture preparation for preventing and fighting infections of farm animals, especially poultry, with pathogenic strains of bacteria sensitive to these bacteriophages.
  • the aim of the invention is to provide production technology for an antimicrobial preparation suitable for use as a feed additive for poultry and pigs, which at the same time would be specific to pathogenic strains of Salmonella spp that cause incidence of salmonellosis, especially in humans.
  • the preparation shall comply with strict safety requirements for feed additives. Prohibition to use antibiotics in animal feed, valid in European Union countries since 1 st January 2006, created a huge demand for feed additives, not containing antibiotics, but having anti-microbial effect.
  • the aim of the present invention is to provide a preparation that could replace the currently used antibiotics.
  • This invention relates to a method of preparing a strain of bacteriophage specific to a selected strain of bacteria, characterized in that:
  • resazurin is added to the culture and the incubation is continued in the dark at 37° C, for at least 3 hours,
  • the colour or fluorescence of culture is being controlled, as well as bacteriophage strain contained in the culture that retains the blue colour or shows no significant increase in fluorescence compared with the control sample, is identified as a strain of bacteriophage specific to a selected strain of bacteria.
  • a sterile sample that was treated with the same incubation is used as a control sample,
  • the selected bacterial strain is a strain of S.enterica serovar Enteritidis.
  • the disclosed method is suitable for an easy and rapid screening of large collections of bacteriophage and allows for easy determination of the titre (lytic strength) of tested phages, which is essential in industrial applications.
  • Another object of the invention is the use of bacteriophages to manufacture a preparation for preventing and fighting infections of farm animals, especially poultry, with pathogenic strains of bacteria sensitive to these bacteriophages.
  • the manufactured preparation is intended to be administered to endangered animals with food or water, at intervals of one to seven days.
  • the manufactured preparation provides at least 200-fold reduction in the level of infection a week after the administration is stopped.
  • the infection to be fought is an infection of poultry with pathogenic strains of Salmonella sp.
  • a bacteriophage strain is selected from the group consisting of those strains disclosed in this application, deposited on 7 th June 2011, in the Polish Collection of Microorganisms, under the following deposit numbers: PCM F/00069 (strain 8 sent 1748), PCM F/00070 (strain 8 sent 65) and PCM F/00071 (strain 3 sent 1), is used.
  • Another object of the invention is a strain of bacteriophage suitable to prevent or fight infections by pathogenic strains of Salmonella sp., selected from the group consisting of: PCM F/00069 (strain 8 sent 1748), PCM F/00070 (strain 8 sent 65) and PCM F/00071 (strain 3 sent 1).
  • the preparation according to the invention is based on natural components of the ecosystem and has no unfavourable influence on organisms other than specific pathogenic bacteria. While commercially available substitutes of antibiotics are based on substances which, like for example, organic acids, non-specifically modulate the bacterial flora, preventing to some extent the growth of undesirable microorganisms, the preparation according to the invention ensures that only pathogenic strains of Salmonella spp are selectively reduced. Unexpectedly, it also appeared that the preparation according to the invention is not maintained in the human or animal body, if there is no Salmonella spp present. In a particular realization, the preparation is suitable for use in animal production, especially to fight Salmonella infection in poultry.
  • Bacteriophage strains disclosed in this application were identified by a process according to the invention. Unexpectedly, they show a wide specificity involving the lysis of at least four specific serotypes of Salmonella and maintain to be stable in refrigerated storage conditions for at least 3 months. Moreover, they can be successfully propagated on an industrial scale without loss of activity and they are not specific to the pro-biotic Lactobacillus bacteria. In order to clarify the invention, it has been illustrated in the accompanying figures which present:
  • Figure 1 The restriction profiles for selected bacteriophages
  • Figure 2 The graphs of the monitored parameters of the conducted experiments
  • FIG. 3 Sample image of ELI S A plates immediately after adding the reaction mixture and after three hours of incubation.
  • Figure 4 The results of thermal stability of selected bacteriophages carried out within three months in three different temperature conditions
  • Figure 5 Results of bacteriophage preparation's cytotoxicity testing with neutral red method. A preparation containing a sterile mixture of bacteriophages was added for 24 h to culture of mouse 3T3 fibroblasts, and cell viability was assessed with the use of neutral red uptake test; Figure 6: Detection of Salmonella bacilli in the experiment which was carried out;
  • FIG. 7 The level of CFU Salmonella in internal organs and intestines of 21 -day-old chicks.
  • the herein description has been supplemented with the following examples which serve for better illustration of the nature of the invention. However, these examples should not be identified with the full scope of the invention.
  • Bacteriophages were isolated from samples provided by the Wastewater Treatment Plants from Lodz, Tru and Tuszyn, Tru. The studies confirmed that the samples collected from sands' separation stage (sand chamber), which is one of the wastewater's treatment processes, are the richest source of viruses. Moreover, the bacteriophages were also obtained from hen feces, provided by a private farmer and VETLAB company specializing in bacterial contamination analysis of farms. Isolation of phages was carried out with the use of Salmonella enterica reference strains, including Typhimurium, Enteritidis and Typhi serovars, as well as several environmental strains. So far, several selected phages were described in details (Table 2).
  • Table 2 The list of obtained bacteriophages and their host strains.
  • specificity of viruses isolated with the use of the plate method was defined by determining the lytic capability of isolated bacteriophages towards 17 selected S. enterica strains, including 7 various serovars selected, 9 strains of Enteritidis serovars isolated from humans and farming animals, as well as the host strains of analyzed bacteriophages (Table 3). In order to confirm the results, the specificity determination of isolated bacteriophages was repeated three times. Table 3. Specificity of selected bacteriophages in relation to chosen reference and environmental strains.
  • Such prepared samples were subjected to the process of isolation of genomic DNA of studied bacteriophages. This procedure uses zircon spheres of 0.1 mm diameter. It also uses extraction with organic solvents and commercial systems for the isolation of genomic DNA.
  • the resulting DNA is used in (1) restriction analysis (three independent experiments using the EcoRl enzyme) generating various restriction profiles for different bacteriophages, which represents an initial gene characterization of phages (Fig. 1).
  • a more detailed genetic characterization is obtained from sequencing the genomes of bacteriophages from our collection, performed with the use of new-generation sequencing techniques, subcontracted to the Macrogen company. Analysis of the results of such sequencing is performed by our research team. It was established that so far obtained sequences of the genomic DNA show high homology towards the bacteriophage from very well explored T5 family and are the lytic bacteriophages.
  • the optimal inoculum volume of bacterial culture was assessed to be 2 x 10 9 CFU for 0.5 1 of culture medium.
  • the temperature of 37°C appeared to be the optimal for bacterial growth.
  • the optimal aeration level was achieved by shaking at 220 rpm in the New Brunswick shaker.
  • the optimization process demonstrated that the addition of 10% of bacteriophage suspension showing titer of 10 9 (50 ml per 500 ml of culture) is the most favourable inoculum amount.
  • the analysis showed that the optimal initial proportion of bacteriophages particles and bacterial cells is 25:1.
  • the optimization studies revealed that the isolated bacteriophages display lytic nature and consequently induction of the lytic cycle is not required.
  • the process of bacteriophage's recovery from culture was performed by ultracentrifugation in Beckman L-80 type ultracentrifuge. Bacterial cultures infected with bacteriophages after proper incubation process (see above) were initially centrifuged for 30 min (3700 g).
  • bacteriophage propagation method in a 10-liters bioreactor 8-liters of working volume was developed.
  • 8 litres of LB medium was prepared and autoclaved (for 20 min. at 120°C) in the bioreactor.
  • sample was taken in order to measure optical density (OD 00 ) of Salmonella Enteritidis 65 initial culture.
  • the crucial parameters of the culture and the final titer of propagated bacteriophages were monitored (Table 4 and 5).
  • the culture was carried out in bioreactor with constant aeration at 1.3 1pm (air volume delivered to the medium during 1 minute) and stirring at 50 rpm. After 40 minutes of the process, stirring intensity was increased from 50 to 100 rpm.
  • samples were taken every 30 minutes for determination of optical density of the culture (OD 6 o 0 ).
  • OD 600 optical density
  • the whole content of bioreactor was centrifuged for 30 minutes at 4°C, at the speed of 4500 rpm/min. Since the technical parameters applied are not effective enough for precise separation of biomass from medium; at the next step the supernatant containing phage particles was micro-filtrated twice with the use of the filtration cross-flow system with membrane cassettes for separation of remaining biomass and sterilization of the obtained phage preparation
  • Propagation process of bacteriophage particles is the first stage of the production line. This is realized by inoculating a bacterial culture of Salmonella in a bioreactor (conditions described above) with bacteriophage particle suspension. During the culture process, phage particles are propagated in bacterial cells leading to cell lysis. Each of all three bacteriophages has to be propagated in a separate culture. So far in our research, a classic 10-liter bioreactor (8 litres of working volume) has been used. In order to carry out this type of culture, previously prepared components are used, including (1) bacterial inoculum and (2) bacteriophage suspension which is added after achieving a suitable optical density (OD 6 oo) of the bacterial culture.
  • OD 6 oo optical density
  • the culture is carried out from 3 to 4 hours and the process enables to obtain a high titer of a propagated bacteriophage at the level of about 10 9 PFU/ml.
  • the culture is transferred in a sterile manner to the next stage of production process by means of peristaltic pump.
  • 100-liter bioreactors or single-use advanced bioreactor bags (up to 15 litres), which lately successfully replace classic bioreactors, are planned to be applied at the production line.
  • bacteriophage suspension can be concentrated 10-fold which allows for increase of the number of phage particles in a given volume. Therefore, a cross-flow filtration system with ultra-filtration membrane of 30 or 50 kD cut-off (depending on the phage), is used. This process allows for 7.5-fold concentration of bacteriophage particles.
  • a mixture of different bacteriophage suspensions obtained in procedures described above, is prepared.
  • the mixture should contain all bacteriophages with very similar titer value.
  • Bacteriophages selected for the preparation show lysis capability of widest spectrum of Salmonella spp bacterial strains from the possessed collection. Subsequently, the preparation is portioned in strictly sterile conditions. Additionally, during this process the final suspension is again subjected to sterilization by means of a single-use, micro-filters (0.22 um).
  • microencapsulation technology is planned in order to enclose bacteriophage particles in alginate capsules.
  • the purpose of this stage is to generate easily absorbable capsules which safely pass through the digestive system and to release gradually the enclosed bacteriophage particles in the target place without irritating the whole organism.
  • the commercially available alamarBlue ® reagent was used for development of the assay useful for measuring the bacteriophage lytic activity.
  • the alamarBlue ® is an indicatory dye which enables fast and accurate quantification of proliferation and cytotoxicity based on chromatic reaction.
  • An easy-to-use reagent takes advantage of the phenomenon of a reduction-oxidation reaction (REDOX) and during the process a resazurin changes its colour from blue (non-fluorescent) to red (fluorescent) as a result of oxidation, which is a consequence of cell metabolic activity. The change of colour is visible with the naked eye. It can be also measured spectrophotometrically or fluorometrically.
  • REDOX reduction-oxidation reaction
  • alamarBlue ® Due to its lack of cell toxicity, alamarBlue ® is especially valuable in observation of bacterial cell differentiation in microbial cultures. This test was adjusted for application on 96-well ELISA plate and two techniques of measurement were elaborated. The first one was intended to assess the lytic activity of bacteriophages. During the test, the so called fresh working mixture was used (prepared just before application on the ELISA plate), which consisted of alamarBlue ® and 20% sterile TweenTM80 solution (3 parts of alamarBlue ® and 1 part of 20% sterile TweenTM80 solution), and was added to wells containing studied Salmonella strain suspension of appropriate density, as well as to wells filled with both Salmonella cell suspension of appropriate density and studied bacteriophage suspension of desired titer.
  • the procedure enables visual determination of the lytic activity of phage particles in relation to the investigated Salmonella strains.
  • the blue colour of the reaction mixture of alamarBlue ® + 20% sterile TweenTM80 solution (3 parts of alamarBlue ® and 1 part of 20% sterile TweenTM80 solution) indicates lack of growth of the studied Salmonella strain and high lytic effect of proper bacteriophage concentration.
  • the mixture should be prepared directly before application into wells on ELISA plate (3 parts of alamarBlue ® and 1 part of 20% sterile TweenTM80 solution).
  • the modified protocol may be applied as a useful tool for estimation of protective effect of bacteriophages against Salmonella Enteritidis growth. Colour change of the reaction mixture of alamarBlue® from blue to red, which is caused by the oxidation associated with metabolic activity, indicates Salmonella cells' growth. The blue colour of the reaction mixture of alamarBlue® + 20% sterile TweenTM80 solution indicates protective effect of phage suspension preventing growth of Salmonella cells.
  • LPS endotoxin concentration
  • Kit produced by Genscript ToxinSensor LAL Endotoxin Assay Kit.
  • Kit produced by LONZA (QCL-1000 Endpoint chromogenic LAL Assay).
  • LAL reagent interacts with endotoxin in analyzed samples resulting in production of a reaction product which is able to react with chromogenic substrate, thus the spectrophotometric measurement is possible.
  • the intensity of the colour is directly proportional to endotoxin concentration.
  • Phage-containing samples were taken at different stages of the technological process (assessment of ultracentrifugation's effectiveness - A1-A2 samples, and phage particles concentration using different membranes cut-off: 100 kDa - B1-B5 samples and 50 kDa - C1-C7 samples) and analyzed for endotoxin level. The results obtained indicate presence of high amount of LPS in samples taken after the phage particles concentration stage (Table 6).
  • Salmonella enterica ser. Enteritidis 65/S/10 strain provided by VETLAB was used to infect broilers, whereas to prepare the bacteriophage agent, three bacteriophages: 3 sent 1, 8sent65, and 8sentl748, isolated from two Salmonella enterica strains (Table 3) and showing a wide spectrum of specificity against different Salmonella serovars, as well as against investigated Enteritidis strains, were used. Based on specificities of the used bacteriophages, specificity of the complete preparation can be assumed (Table 7).
  • Bacteriophage preparation was prepared in the following manner: each of the three bacteriophages were subjected to the optimized procedure of propagation, and afterwards the obtained phage suspensions were mixed, so that their titer values in the final product were similar. Two mixtures with different phage concentrations were prepared: high concentration containing 2.0 x 10 8 PFU/ml and low concentration containing 2.0 x 10 6 PFU/ml. Afterwards, the mixtures were portioned and sterilized using microfiltration. Analysis of microbial contamination showed no presence of bacteria in the bacteriophage preparation used.
  • the bacteriophage preparation was administered to chickens placed in boxes 1 (low concentration of 2.0 x 10 6 PFU/ml, marked as FN), 2 and 5 (high concentration of 2.0 x 10 8 PFU/ml, marked as Fw).
  • the preparation was administered to roosters once a day for first 14 days of their lives.
  • the bacteriophage agent was not administered to chickens from boxes 4 and 5.
  • the rearing time was 21 days and during this period only five birds from different boxes died (Table 8). Since the detected death rate was minimal and did not depend on a given group of chickens therefore the death rate could not have been the result of the administration of the phage preparation.
  • Table 8 The scheme of administration of bacteria and bacteriophages, as well as birds' viability.
  • Detection of Salmonella bacilli's presence in analyzed samples was carried out by an accredited laboratory -VETLAB (Brudzew, Tru). In 2008, this laboratory received authorization of the Chief Veterinary Officer (no. GIWhig-5120-23/08) to perform detection of Salmonella bacilli by means of bacteriological-qualitative method.
  • Salmonella bacilli were not detected in analyzed samples of internal organs and intestines of one-day-old nestlings, meconium, as well as smears from boxes before insertion of nestlings.
  • the lack of Salmonella bacilli or different level of its detection in case of analysis of feces from 21 days of experiment, as well as sole smears analysis on 3 rd , 15 th and 21 st day of life (Table 9), and internal organs analysis of 21 -days-old broilers ( Figure 7) was dependent on the box under investigation. That is, as it was anticipated, no Salmonella bacilli were detected in chickens from boxes 4 and 5.
  • Samples analyzed for bacteriophage presence were collected from feces during 21 days of the experiment and from smears from all boxes before introduction of nestlings, before infection and also a day and a week after discontinuation of phage treatment. No bacteriophages were detected in internal organs. It was observed that lack of bacteriophages or different level of their detection in birds' feces (Table 10) and sole smears analyses (Table 11) depended on the given box of chicken under analysis. That is, bacteriophages were detected in feces of chickens form boxes 1, 2 and 5, which were administered the phage agent.
  • the preparation is safe for poultry.
  • Bacteriophages pass through the intestinal tract and reach the feces and litter.
  • Bacteriophages do not enter internal organs of the birds.
  • Bacteriophages prevent the appearance of bacteria in feces of experimentally infected birds.
  • Bacteriophages decrease 200-fold the infection level one week after discontinuation of the phage treatment.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Birds (AREA)
  • Food Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Animal Husbandry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Fodder In General (AREA)

Abstract

A method for obtaining a strain of bacteriophage specific to a selected strain of bacteria was found as well as bacteriophage strains obtained in this way. Moreover, application of bacteriophages in manufacturing of the preparation for preventing and fighting infections of farm animals, especially poultry, with pathogenic strains of bacteria sensitive to these phages was described.

Description

The method of obtaining a strain of bacteriophage, specific strains of bacteriophage and use thereof
This invention relates to a method for preparing a strain of bacteriophage specific to a selected strain of bacteria, bacteriophage strains obtained in this way and the application of bacteriophages to manufacture preparation for preventing and fighting infections of farm animals, especially poultry, with pathogenic strains of bacteria sensitive to these bacteriophages.
The aim of the invention is to provide production technology for an antimicrobial preparation suitable for use as a feed additive for poultry and pigs, which at the same time would be specific to pathogenic strains of Salmonella spp that cause incidence of salmonellosis, especially in humans. The preparation shall comply with strict safety requirements for feed additives. Prohibition to use antibiotics in animal feed, valid in European Union countries since 1st January 2006, created a huge demand for feed additives, not containing antibiotics, but having anti-microbial effect.
The aim of the present invention is to provide a preparation that could replace the currently used antibiotics.
Unexpectedly, such preparation was successfully obtained in the present invention.
This invention relates to a method of preparing a strain of bacteriophage specific to a selected strain of bacteria, characterized in that:
a) a collection of bacteriophage strains containing a strain of bacteriophage specific to a selected strain of bacteria is obtained,
b) culture of a selected strain of bacteria on a sterile culture medium is conducted, c) the culture samples are applied on the special multi-well measuring plate, then a suspension of tested bacteriophage strain at various concentrations is added and it is incubated at 37° C for at least 4 hours,
d) resazurin is added to the culture and the incubation is continued in the dark at 37° C, for at least 3 hours,
e) the colour or fluorescence of culture is being controlled, as well as bacteriophage strain contained in the culture that retains the blue colour or shows no significant increase in fluorescence compared with the control sample, is identified as a strain of bacteriophage specific to a selected strain of bacteria. A sterile sample that was treated with the same incubation is used as a control sample,
f) identified strain of bacteriophage specific to a selected strain of bacteria is propagated. Favourably, the selected bacterial strain is a strain of S.enterica serovar Enteritidis. The disclosed method is suitable for an easy and rapid screening of large collections of bacteriophage and allows for easy determination of the titre (lytic strength) of tested phages, which is essential in industrial applications.
Another object of the invention is the use of bacteriophages to manufacture a preparation for preventing and fighting infections of farm animals, especially poultry, with pathogenic strains of bacteria sensitive to these bacteriophages. The manufactured preparation is intended to be administered to endangered animals with food or water, at intervals of one to seven days. Favourably, the manufactured preparation provides at least 200-fold reduction in the level of infection a week after the administration is stopped.
Favourably, the infection to be fought is an infection of poultry with pathogenic strains of Salmonella sp., whereas in order to manufacture the preparation, a bacteriophage strain is selected from the group consisting of those strains disclosed in this application, deposited on 7th June 2011, in the Polish Collection of Microorganisms, under the following deposit numbers: PCM F/00069 (strain 8 sent 1748), PCM F/00070 (strain 8 sent 65) and PCM F/00071 (strain 3 sent 1), is used.
Another object of the invention is a strain of bacteriophage suitable to prevent or fight infections by pathogenic strains of Salmonella sp., selected from the group consisting of: PCM F/00069 (strain 8 sent 1748), PCM F/00070 (strain 8 sent 65) and PCM F/00071 (strain 3 sent 1).
The preparation according to the invention is based on natural components of the ecosystem and has no unfavourable influence on organisms other than specific pathogenic bacteria. While commercially available substitutes of antibiotics are based on substances which, like for example, organic acids, non-specifically modulate the bacterial flora, preventing to some extent the growth of undesirable microorganisms, the preparation according to the invention ensures that only pathogenic strains of Salmonella spp are selectively reduced. Unexpectedly, it also appeared that the preparation according to the invention is not maintained in the human or animal body, if there is no Salmonella spp present. In a particular realization, the preparation is suitable for use in animal production, especially to fight Salmonella infection in poultry.
Bacteriophage strains disclosed in this application were identified by a process according to the invention. Unexpectedly, they show a wide specificity involving the lysis of at least four specific serotypes of Salmonella and maintain to be stable in refrigerated storage conditions for at least 3 months. Moreover, they can be successfully propagated on an industrial scale without loss of activity and they are not specific to the pro-biotic Lactobacillus bacteria. In order to clarify the invention, it has been illustrated in the accompanying figures which present:
Figure 1 : The restriction profiles for selected bacteriophages;
Figure 2: The graphs of the monitored parameters of the conducted experiments;
Figure 3: Sample image of ELI S A plates immediately after adding the reaction mixture and after three hours of incubation. The OD600 optical density of the used suspension of S. enterica ser. Enteritidis ATCC 13076 strain amounting to 0.05, 0.1, 0.25, 0.5, 1.0 and 2.0, respectively corresponds to the density of cells - 8 x 105, 1.05 x 106, 7.0 x 106, 3.5 x 107, 1.4 x 108 and 3.8 x 108;
Figure 4: The results of thermal stability of selected bacteriophages carried out within three months in three different temperature conditions;
Figure 5: Results of bacteriophage preparation's cytotoxicity testing with neutral red method. A preparation containing a sterile mixture of bacteriophages was added for 24 h to culture of mouse 3T3 fibroblasts, and cell viability was assessed with the use of neutral red uptake test; Figure 6: Detection of Salmonella bacilli in the experiment which was carried out;
Figure 7: The level of CFU Salmonella in internal organs and intestines of 21 -day-old chicks. The herein description has been supplemented with the following examples which serve for better illustration of the nature of the invention. However, these examples should not be identified with the full scope of the invention.
Example 1. Isolation and description of bacteriophages
Establishing a bank of Salmonella strains (serovars) most frequently isolated from humans and farm animals
The set of 108 Salmonella ssp. strains, consisting of the most frequently isolated serovars, was collected for the necessity of the project (Table 1). These strains are applied in determination of specificity of purified bacteriophages. The collection is comprised of both reference strains available in public repositories, as well as isolates obtained owing to cooperation with the VETLAB company (Brudzew, Poland) and State Sanitary Inspection. Table 1. The list of Salmonella ent erica serovars and their origins.
Number of
No. Serovar Source
strains
1 Berta 1 VetLab
2 Brandenburg 1 State Sanitary Inspection
3 Coeln 1 VetLab
4 Colindale 1 VetLab
5 Derby 1 VetLab
6 Enteritidis 1 ATCC
1 State Sanitary Inspection
58 VetLab
7 Gallimarum 1 VetLab
Pullorum
8 Hadar 2 VetLab
1 State Sanitary Inspection
9 Heidelberg 1 VetLab
10 Infantis 6 VetLab
1 State Sanitary Inspection
11 Mbandaka 1 VetLab
12 Moscow 1 VetLab
13 Newport 5 VetLab
14 Paratyphi 1 ATCC
15 Senfenberg 1 VetLab
16 Typhi 1 ATCC
17 Typhimurium 1 ATCC
1 State Sanitary Inspection
10 VetLab
18 Virchow 9 Vetlab
Isolation of bacteriophages, from environmental samples, showing activity towards selected serovars of reference Salmonella ssp strains
Bacteriophages were isolated from samples provided by the Wastewater Treatment Plants from Lodz, Poland and Tuszyn, Poland. The studies confirmed that the samples collected from sands' separation stage (sand chamber), which is one of the wastewater's treatment processes, are the richest source of viruses. Moreover, the bacteriophages were also obtained from hen feces, provided by a private farmer and VETLAB company specializing in bacterial contamination analysis of farms. Isolation of phages was carried out with the use of Salmonella enterica reference strains, including Typhimurium, Enteritidis and Typhi serovars, as well as several environmental strains. So far, several selected phages were described in details (Table 2).
Table 2. The list of obtained bacteriophages and their host strains.
No. Bacteriophage Source Host strain
1 lstl Wastewater treatment plant S. enterica ser. Typhimurium LT2
2 1 sent3 Wastewater treatment plant
3 lsent4 Wastewater treatment plant
S. enterica ser Enteritidis ATCC
4 3 sent 1 Wastewater treatment plant
13076
5 4sentl Private farm
6 6sentl Private farm
7 5 sent 1 VetLab
S. enterica ser. Enteritidis 65/S/10
8 8sent65 VetLab
9 8sentl748 VetLab S. enterica ser. Enteritidis 1748
10 2styp4 VetLab
1 1 2styp5 VetLab S. enterica ser. Typhi ATCC 13311
6stypl Private farm
All phages intended for further investigations were purified with the use of the screening method in order to obtain a single plaque on the LB (Luria-Bertani) plates. This procedure required at least five time application of the screening process.
Initially, specificity of viruses isolated with the use of the plate method was defined by determining the lytic capability of isolated bacteriophages towards 17 selected S. enterica strains, including 7 various serovars selected, 9 strains of Enteritidis serovars isolated from humans and farming animals, as well as the host strains of analyzed bacteriophages (Table 3). In order to confirm the results, the specificity determination of isolated bacteriophages was repeated three times. Table 3. Specificity of selected bacteriophages in relation to chosen reference and environmental strains.
Figure imgf000007_0001
Enteritidis _|_ nd + nd
1446/S/09 K-31
Enteritidis
+ + nd 1 1 nd
1535/S/09
Enteritidis
+ + + nd + + nd
2050/S/09 K-4
nd - not determined
The resulting phages, propagated in the host strain, were concentrated by PEG8000. Such prepared samples were subjected to the process of isolation of genomic DNA of studied bacteriophages. This procedure uses zircon spheres of 0.1 mm diameter. It also uses extraction with organic solvents and commercial systems for the isolation of genomic DNA. The resulting DNA is used in (1) restriction analysis (three independent experiments using the EcoRl enzyme) generating various restriction profiles for different bacteriophages, which represents an initial gene characterization of phages (Fig. 1). A more detailed genetic characterization is obtained from sequencing the genomes of bacteriophages from our collection, performed with the use of new-generation sequencing techniques, subcontracted to the Macrogen company. Analysis of the results of such sequencing is performed by our research team. It was established that so far obtained sequences of the genomic DNA show high homology towards the bacteriophage from very well explored T5 family and are the lytic bacteriophages.
Example 2. Manufacture of the preparation
Determination and optimization of bacteriophage propagation process conditions in a Salmonella ssp. culture at a laboratory scale
Optimization was carried out with the use of Salmonella enterica ser. Enteritidis ATCC 13076 strain. The parameters taken into consideration were as follows: inoculum volume of a bacterial culture and bacteriophages, time of the pure culture process and incubation of infected culture, temperature of the culture, aeration level, pH of medium and conditions required for lytic cycle induction.
The optimal inoculum volume of bacterial culture was assessed to be 2 x 109 CFU for 0.5 1 of culture medium. The optimized culture process was being carried out until optical density reached the level of OD60o = 0.5, which was achieved after 3 hours of incubation. The temperature of 37°C appeared to be the optimal for bacterial growth. The optimal aeration level was achieved by shaking at 220 rpm in the New Brunswick shaker. The optimal culture's growth was observed on the LB medium of pH = 7.0. The optimization process demonstrated that the addition of 10% of bacteriophage suspension showing titer of 109 (50 ml per 500 ml of culture) is the most favourable inoculum amount. Also, the analysis showed that the optimal initial proportion of bacteriophages particles and bacterial cells is 25:1. Moreover, the optimization studies revealed that the isolated bacteriophages display lytic nature and consequently induction of the lytic cycle is not required.
The process of bacteriophage's recovery from culture was performed by ultracentrifugation in Beckman L-80 type ultracentrifuge. Bacterial cultures infected with bacteriophages after proper incubation process (see above) were initially centrifuged for 30 min (3700 g).
Afterwards, the supernatant was transferred into Beckman type ultracentrifugation tubes and ultracentrifuged for 2 hours (200 000 g). This procedure allowed for simultaneous purification and concentration of phage preparation.
Optimization of Salmonella spp reference strain culture in 10-liter s scale
In the next step of the optimization, bacteriophage propagation method in a 10-liters bioreactor (8-liters of working volume) was developed. For this purpose, 8 litres of LB medium was prepared and autoclaved (for 20 min. at 120°C) in the bioreactor. Before inoculation with 200 ml of Salmonella Enteritidis 65 strain, the medium was aerated to 90% - 100% and heated up to 37°C. The inoculum was a 16-hour bacterial culture showing optical density of approximately OD600 = 5.0 (4.5-5*109 CFU/ml). After inoculation of the medium, sample was taken in order to measure optical density (OD 00) of Salmonella Enteritidis 65 initial culture. The crucial parameters of the culture and the final titer of propagated bacteriophages were monitored (Table 4 and 5). The culture was carried out in bioreactor with constant aeration at 1.3 1pm (air volume delivered to the medium during 1 minute) and stirring at 50 rpm. After 40 minutes of the process, stirring intensity was increased from 50 to 100 rpm. During the culture process, samples were taken every 30 minutes for determination of optical density of the culture (OD6o0). When the bacterial culture's optical density (OD600) of the value of 0.48-0.55 was achieved, a 3sentl bacteriophage suspension of suitable titer was added into the culture, in the volumes as follows:
• 800 ml in case of experiment 1,
• 700 ml in case of experiment 2, as well as
• 200 ml in case of experiment 3 and 4.
From this point of time, the culture was carried out for 4 hours with constant aeration and stirring (see above). The changes of optical density and phage propagation kinetics were monitored by taking samples every hour. During the process, culture parameters, including pH, p02 (aeration level indicated in %), temperature of the medium and correct level of stirring, were monitored. Every monitored parameter was recorded with the use of software designed for documentation of the course of culture process (Figure 2), except experiment 1 , due to technical problems experienced with initializing of the software. During the conducted experiments, progressing decrease of dissolved oxygen level in medium (increase of oxygen consumption by bacterial cells due to their growth in the culture), as well as small pH fluctuations within the range of 7.2-6.7, were noted.
Regardless of the phage suspension volume used (from 200 to 800 ml with titer of 1.3-2.3 x 109 PFU/ml), high propagated bacteriophage titer of about 109 PFU/ml was achieved. Table 4. Parameters of 3 sent 1 phage's propagation in 10 litres of Salmonella Enteritidis 65 strain culture.
Volumes applied [ml]
Experiment 1 Experiment 2 Experiment 3 Experiment 4
Bacterial inoculum 200 ml 200 ml 200 ml 200 ml
Phage suspension 800 ml 700 ml 200 ml 200 ml
OD600
Beginning of the process 0.097 0.089 0.070 0.070
Before addition of phage
0.488 0.501 0.501 0.535 suspension
lh of phage's propagation 0.589 0.720 0.856 0.477
2h of phage's propagation 0.150 0.286 0.632 0.198
3h of phage's propagation 0.1 10 0.210 0.372 0.160
4h of phage's propagation 0.068 0.182 0.320 0.166
Table 5. Number of propagated 3sentl phage particles.
Density of phage suspension [PFU/ml]
Experiment 1 Experiment 2 Experiment 3 Experiment 4
Initial phage 2.32xl09 1.17xl09 1.33xl09 1.44xl09 suspension PFU/ml PFU/ml PFU/ml PFU/ml lh of phage's 6.20x109 1.05xl09 1.42xl09 4.94x109 propagation PFU/ml PFU/ml PFU/ml PFU/ml
2h of phage's 5.54xl0y 4.32xl09 5.98xl09 3.90x109 propagation PFU/ml PFU/ml PFU/ml PFU/ml
3h of phage's 6.26xl09 3.84x109 5.72xl09 5.80xl09 propagation PFU/ml PFU/ml PFU/ml PFU/ml
4h of phage's 7.94xl09 4.16xl09 4.26x109 3.16xl09 propagation PFU/ml PFU/ml PFU/ml PFU/ml
After 4 hours of bacteriophage propagation process, the whole content of bioreactor was centrifuged for 30 minutes at 4°C, at the speed of 4500 rpm/min. Since the technical parameters applied are not effective enough for precise separation of biomass from medium; at the next step the supernatant containing phage particles was micro-filtrated twice with the use of the filtration cross-flow system with membrane cassettes for separation of remaining biomass and sterilization of the obtained phage preparation
CONCLUSIONS: The performed biotechnological processes enabled us to describe initial restrictions for phage particles propagation method using Salmonella spp strain culture in 10- liters bioreactor scale.
• Volume of medium - 8 litres;
• Volume of Salmonella Enteritidis 65 inoculum (OD600 = 5 ; 4.5-5 x 109 CFU/ml) - 200 ml;
• Volume of phage suspension (titer 109 PFU/ml) - 200 ml;
• Time of phage particles propagation process - 3 hours;
• Parameters of centrifugation - 30 minutes at 4°C, at the speed of 4500 rpm/min;
• Two-time microfiltration (membrane with pore size of 0.22 μιη);
• Titration procedure of the obtained phage preparation;
Development of the preparation 's manufacturing and purification technology
Stages of bacteriophage preparation's manufacturing process
1. Bioreactor culture.
Propagation process of bacteriophage particles is the first stage of the production line. This is realized by inoculating a bacterial culture of Salmonella in a bioreactor (conditions described above) with bacteriophage particle suspension. During the culture process, phage particles are propagated in bacterial cells leading to cell lysis. Each of all three bacteriophages has to be propagated in a separate culture. So far in our research, a classic 10-liter bioreactor (8 litres of working volume) has been used. In order to carry out this type of culture, previously prepared components are used, including (1) bacterial inoculum and (2) bacteriophage suspension which is added after achieving a suitable optical density (OD6oo) of the bacterial culture. After addition of phage suspension, the culture is carried out from 3 to 4 hours and the process enables to obtain a high titer of a propagated bacteriophage at the level of about 109 PFU/ml. Once the propagation procedure is finished, the culture is transferred in a sterile manner to the next stage of production process by means of peristaltic pump. In the future, 100-liter bioreactors or single-use advanced bioreactor bags (up to 15 litres), which lately successfully replace classic bioreactors, are planned to be applied at the production line.
2. Removal of biomass. Since the total lysis of bacterial culture during the bioreactor incubation process is not possible, a subsequent stage separation of the biomass from phage-containing culture liquid is required. Therefore, at the first stage, the culture is transferred to a centrifuge, and then microfiltration process is carried out twice using cross-flow filtration system containing membrane with pore size of 0.22 μιη. This procedure allows to obtain a sterile bacteriophage suspension with very small decrease in phage particles titer. Once the filtration process is finished, the suspension is transferred in a sterile manner to the next stage of production process by means of peristaltic pump. In the future, expansion of this stage of the production line by purchasing additional filtration systems is planned. This would allow for treatment of the biological material obtained from a single bioreactor culture without the need for cleaning and sterilization of the filtration equipment used during this stage.
3. Product concentration (optional).
Depending on the product demand, bacteriophage suspension can be concentrated 10-fold which allows for increase of the number of phage particles in a given volume. Therefore, a cross-flow filtration system with ultra-filtration membrane of 30 or 50 kD cut-off (depending on the phage), is used. This process allows for 7.5-fold concentration of bacteriophage particles.
4. Removal of potential endotoxin contamination.
In order to eliminate endotoxin remaining after lysis of bacterial cells induced by bacteriophages during the biotechnological process, application of special adsorption columns is planned. These columns will contain resin suitable for removing endotoxin of size and capacity depending on the volume of the phage-containing preparation.
5. Preparation of the product in liquid phase.
At this stage, a mixture of different bacteriophage suspensions, obtained in procedures described above, is prepared. The mixture should contain all bacteriophages with very similar titer value. Bacteriophages selected for the preparation show lysis capability of widest spectrum of Salmonella spp bacterial strains from the possessed collection. Subsequently, the preparation is portioned in strictly sterile conditions. Additionally, during this process the final suspension is again subjected to sterilization by means of a single-use, micro-filters (0.22 um).
6. Microencapsulation (optional)
Depending on whether the product is required in liquid or solid form, implementation of microencapsulation technology is planned in order to enclose bacteriophage particles in alginate capsules. The purpose of this stage is to generate easily absorbable capsules which safely pass through the digestive system and to release gradually the enclosed bacteriophage particles in the target place without irritating the whole organism.
Example 3. Research of the effectiveness and safety of the preparation
In vitro research
Development and optimization of the highly efficient and automated colorimetric method for measurement of bacteriophage preparation activity
The commercially available alamarBlue® reagent was used for development of the assay useful for measuring the bacteriophage lytic activity. The alamarBlue® is an indicatory dye which enables fast and accurate quantification of proliferation and cytotoxicity based on chromatic reaction. An easy-to-use reagent takes advantage of the phenomenon of a reduction-oxidation reaction (REDOX) and during the process a resazurin changes its colour from blue (non-fluorescent) to red (fluorescent) as a result of oxidation, which is a consequence of cell metabolic activity. The change of colour is visible with the naked eye. It can be also measured spectrophotometrically or fluorometrically. Due to its lack of cell toxicity, alamarBlue® is especially valuable in observation of bacterial cell differentiation in microbial cultures. This test was adjusted for application on 96-well ELISA plate and two techniques of measurement were elaborated. The first one was intended to assess the lytic activity of bacteriophages. During the test, the so called fresh working mixture was used (prepared just before application on the ELISA plate), which consisted of alamarBlue® and 20% sterile Tween™80 solution (3 parts of alamarBlue® and 1 part of 20% sterile Tween™80 solution), and was added to wells containing studied Salmonella strain suspension of appropriate density, as well as to wells filled with both Salmonella cell suspension of appropriate density and studied bacteriophage suspension of desired titer. The procedure enables visual determination of the lytic activity of phage particles in relation to the investigated Salmonella strains. The blue colour of the reaction mixture of alamarBlue® + 20% sterile Tween™80 solution (3 parts of alamarBlue® and 1 part of 20% sterile Tween™80 solution) indicates lack of growth of the studied Salmonella strain and high lytic effect of proper bacteriophage concentration. Colour change of the reaction mixture of alamarBlue® + 20% sterile Tween™80 solution (3 parts of alamarBlue® and 1 part of 20% sterile Tween™80 solution) from blue to red, caused by the oxidation associated with metabolic activity, indicates growth of Salmonella cells and lack or low lytic effect of proper bacteriophage concentration in relation to the investigated Salmonella strain. A detailed experimental protocol enabling quantitative assessment of the lytic activity of bacteriophages, as well as a drawing presenting the results of a selected experiment conducted for the 3sentl bacteriophage in relation to Salmonella enterica ser. Enteritidis ATCC 13076 strain (Figure 3), are presented below.
1. Add 100 μΐ of Salmonella spp. culture suspension of proper optical density (OD600) relating to appropriate number of colony forming units (CFU/1 ml)1 into each well of the first row in columns from 1 to 12. In detail: suspension of the optical density of 0.05, 0.1, 0.25, 0.5, 1.0 and 2.0 into the plate wells: 1 and 7, 2 and 8, 3 and 9, 4 and 10, 5 and 11, as well as 6 and 12, respectively.
2. Add 100 μΐ of phage suspension at concentration of 6.5 x 109 PFU (plaque forming units) into each well of the first row in columns from 1 to 6. The volume proportion of bacterial to phage suspension is 1 : 1.
3. Similarly, add 75 μΐ of Salmonella spp. culture suspension of proper optical density and 125 μΐ of phage suspension into wells of the second row. The volume proportion of bacterial to phage suspension is 1 : 1.5.
4. Similarly, add 50 μΐ of Salmonella spp. culture suspension of proper optical density and 150 μΐ of phage suspension into wells of the third row. The volume proportion of bacterial to phage suspension is 1 :3.
5. Prepare the controls; add sterile LB medium instead of phage suspension into each well of the first, second and third row in columns from 7 to 12 (control of Salmonella strain growth of given densities). Additionally, add phage suspension into each well of 6th, 7th and 8th row in column 3 (control of phage suspension contamination) and add LB medium into each well of 7th and 8th row in column 7 (control of contamination of the medium applied to dilute the culture in investigated and control set).
6. Cover the ELISA plate with sterile lids and incubate for 4 h at 37°C. After the incubation stage, add 50 μΐ of alamarBlue® + 20% sterile Tween™80 reaction mixture2 into each well plate. Due to the reaction mixture's susceptibility to light, protect the plate with aluminium foil. Continue the incubation for the next 3 h in 37°C. Perform visual observation every 30 minutes.
1 Relation between the OD^oo optical density and the CFU value should be determined experimentally in several independent approaches.
2The mixture should be prepared directly before application into wells on ELISA plate (3 parts of alamarBlue® and 1 part of 20% sterile Tween™80 solution). The modified protocol may be applied as a useful tool for estimation of protective effect of bacteriophages against Salmonella Enteritidis growth. Colour change of the reaction mixture of alamarBlue® from blue to red, which is caused by the oxidation associated with metabolic activity, indicates Salmonella cells' growth. The blue colour of the reaction mixture of alamarBlue® + 20% sterile TweenTM80 solution indicates protective effect of phage suspension preventing growth of Salmonella cells. The detailed protocol:
1. Add 20 ml of LB medium to 100 ml Erlenmayer conical, flat-bottom flasks and autoclave.
2. Inoculate 20 ml of sterile LB liquid medium with S. Enteritidis strain and incubate the culture overnight at 37°C with shaking (rpm=T50). The suspension shall be stored in refrigerator at 4°C not longer than for 1 week and treated as inoculum for current cultures.
3. Inoculate 20 ml sterile LB liquid medium (in 100 ml Erlenmayer flasks) with 20 μΐ of S. Enteritidis strain and incubate the culture for 1 h at 37°C with shaking (rpm=T50).
4. Make appropriate dilutions of the suspension in LB. Dilutions should contain 2000, 200 and 20 bacterial cells in 1 ml. Use for experiments with phage suspension showing protective effect.
5. Mix 100 μΐ of the appropriate dilution of S. Enteritidis bacterial cells with 100 μΐ of bacteriophage suspension and add the mixtures into the sequential wells of 96-wells titer plate.
6. Prepare the controls; appropriate dilutions of S. Enteritidis suspension which will serve as bacterial growth control, as well as the bacteriophage suspension and a clear LB medium as the controls of microbial contamination.
7. Cover the titer plate with a lid and incubate for 4 h at 37°C.
8. Cover the titer plate with a lid and protect with aluminium foil against admission of light, then continue the incubation for next 4 h at 37°C. Perform the reading, after 4 hours of the incubation process.
Research of thermal stability of bacteriophages
Analysis of thermal stability of bacteriophages storage was carried out for 3 months at three different temperatures: -20 0 C, +4 ° C and at room temperature. The stability was measured by determining phage titer by means of plate count at the beginning of the experiment, after one month and after three months of storage in the mentioned above temperatures. Bacteriophages were suspended in LB medium after propagation and purification from bacterial cells. The results indicate that some of bacteriophages of the existing collection, namely 3sentl, 8sent65 and 8sentl748 (Fig. 4), retain their title at the order of magnitude within three months of storage at -20 ° C or 4 ° C, contrary to other phages, e.g.: lstl or 2styp5 (Fig. 4), which is important in view of durability.
Research of bacteriophage preparation 's safety
Determination of endotoxin level
Determination of endotoxin concentration (LPS), the major component of cell's wall of gram negative bacteria, was performed using LAL test (Limulus Amebocyte Lysate). The LAL tests are available as ready-to-use kits for colorimetric measurement of LPS level and activity:
1. Kit produced by Genscript (ToxinSensor LAL Endotoxin Assay Kit).
2. Kit produced by LONZA (QCL-1000 Endpoint chromogenic LAL Assay).
In these tests, LAL reagent interacts with endotoxin in analyzed samples resulting in production of a reaction product which is able to react with chromogenic substrate, thus the spectrophotometric measurement is possible. The intensity of the colour is directly proportional to endotoxin concentration.
Phage-containing samples were taken at different stages of the technological process (assessment of ultracentrifugation's effectiveness - A1-A2 samples, and phage particles concentration using different membranes cut-off: 100 kDa - B1-B5 samples and 50 kDa - C1-C7 samples) and analyzed for endotoxin level. The results obtained indicate presence of high amount of LPS in samples taken after the phage particles concentration stage (Table 6).
Table 6. Results of LPS concentration in analyzed samples.
LPS
Sample
Description concentration No.
EU/ml
Sample containing pellets (phages) after ultracentrufugation
Al >106
suspended in SM buffer
A2 Sample contaning supernatant after ultracentrifugation 106 345
Initial sample - medium contaning phages after seperation of bacterial
Bl >106
cells and sterilization
B2 10-fold concentrated preparation (retentate) 156 389
B3 Permeate - liquid filtered through a concentration membrane 4 888 Saline used to flush the membrane after the end of filtration process,
B4 55
collected as permeate
Saline used to flush the membrane after the end of filtration process,
B5 0.5
collected as retentate
Initial sample - medium contaning phages after seperation of bacterial
CI 21 1 327 cells and sterilization
C2 Permeate - liquid filtered through a concentration membrane 25
C3 10-fold concentrated preparation (retentate) 1.36 x 1010
Saline used to flush the membrane after the end of filtration process,
C4 1.69 x 109 collected as retentate (first sample 100 ml)
Saline used to flush the membrane after the end of filtration process,
C5 1.32 x 109 collected as retentate (second sample 200 ml)
Saline used to flush the membrane after the end of filtration process,
C6 1.05 x 108 collected as retentate (third sample 200 ml)
Saline used to flush the membrane after the end of the filtration
C7 1 549
process, collected as retentate (fourth sample 500 ml)
Cytotoxicity analysis
Investigation was carried out by means of the neutral red uptake assay. The test was performed with 96-wells plates using 3T3 cell line. 3T3 cells are mouse-derived, not- transformed fibroblasts conventionally used for in vitro toxicity analysis. Analysis was carried out on the preparation contaning a mixture of three different phages in 4 serial dilutions. Measurements were performed in duplicates and in 5 independent repetitions. Obtained absorbance values were used for calculation of % of cells' viability by comparing the absorbance of analyzed sample with absorbance of control sample (i.e. cells incubated in culture medium) (Figure 5).
Cytotoxicity test using 3T3 cell line:
1. Put 10 000 3T3 fibroblasts suspended in standard culture medium to each well of 96- wells plate and incubate for 24 hours in the incubator (37°C; 5% C02 ).
2. Remove culture medium and add bacteriophage preparation diluted in culture medium. Continue the incubation for next 24 hours (37°C; 5% C02 ).
3. After the incubation, remove medium containing phage preparation, wash the monolayer of PBS fibroblasts and incubate with neutral red solution in PBS for 3 hours (37°C; 5% C02 ). 4. Remove neutral red solution, wash with PBS and induce cell lysis. Measure the amount of absorbed dye by colorimetric method.
Obtained results indicate lack of cytotoxic activity of bacteriophage preparation even at high concentrations. Consequently, acute cytotoxicity is not expected to appear after using this preparation in vivo at phage concentration of at least up to 108 particles.
In vivo research
Determination of effectiveness and safety of prototype bacteriophage preparation applied against salmonellosis in chicken broilers.
The study was carried out in cooperation with the University of Warmia and Mazury, as well as VETLAB.
Purpose: To evaluate the possibility of using bacteriophages in protection against salmonellosis infections in broiler chickens.
Salmonella enterica ser. Enteritidis 65/S/10 strain provided by VETLAB was used to infect broilers, whereas to prepare the bacteriophage agent, three bacteriophages: 3 sent 1, 8sent65, and 8sentl748, isolated from two Salmonella enterica strains (Table 3) and showing a wide spectrum of specificity against different Salmonella serovars, as well as against investigated Enteritidis strains, were used. Based on specificities of the used bacteriophages, specificity of the complete preparation can be assumed (Table 7). Bacteriophage preparation was prepared in the following manner: each of the three bacteriophages were subjected to the optimized procedure of propagation, and afterwards the obtained phage suspensions were mixed, so that their titer values in the final product were similar. Two mixtures with different phage concentrations were prepared: high concentration containing 2.0 x 108 PFU/ml and low concentration containing 2.0 x 106 PFU/ml. Afterwards, the mixtures were portioned and sterilized using microfiltration. Analysis of microbial contamination showed no presence of bacteria in the bacteriophage preparation used.
Table 7. Assumed specificity of the preparation based on specificity of phages included.
Serovar Strain 3 sent 1 8sentl 48 8sent65 PREPARATION
Typhimurium LT2 + + + +
1751 - + -
Typhi ATCC 1331 1 + + + +
Paratyphi A ATCC 19150 - + -
Infantis 789 , - - -
Brandenburg 584 + + + +
Hadar 817 + + + + Enteritidis D ATCC 13076 + + + +
1748 + + + +
65/S/10 + + + +
249 + + + +
1014/S/09 K-l + + + +
1192/S/09 K-8 + + -
1250/S/09 + + + +
1446/S/09 K-31 + + + +
1535/S/09 + + + +
2050/S/09 K-4 + + + +
Farm "K" K-3 + + + +
Farm "K" K-6 + + + +
Farm "K" K-9 + - -
Farm "K" K-10 + + -
Farm "K" K-l l + - -
Farm "K" K-l 2 + - -
Farm "K" K-l 4 - + + + +
Farm "K" K-l 8
Pac K-ground - + +
Pac K-floor + + + +
W/K-6 + + + +
W K-7 + + -
W/K-9 + + + +
64/S/10 + + + +
65/S/10 + + + +
517/S/09 + + + +
571/S/09 + + + +
833/S/09 + + + +
838/S/09 + - +
838/S/09 B + + + +
847/S/09 + + + +
848/S/09 + - -
865/S/09 + + + +
866/S/09 + + + +
945/S/09 + + + +
975/S/09 + + + +
1013/S/09 K-4 + + + +
1021/S/09 + + + + 1022/S/09 K-9 + + + +
1044/S/09 K-2 + - +
1047/S/09 K-l + + + +
1048/S/09 Κ-8 + + + +
1061/S/09 K-5
1067/S/09 Κ-2 + - -
1067/S/09 Κ-3 + + + +
1085/S/09 MEK + + + +
1106/S/09 K-1 + + + +
1143/S/09 + + + +
1 171/S/09 + + + +
1206/S/09 ΜΕΚ + + + +
1231/S/09 + + + +
1250/S/09 + + + +
1257/S/09 Κ-7 + + + +
1422/S/09 ΜΕΚ + + + +
1445/S/09 Κ-46 + - +
1465/S/09 ΜΕΚ + + + +
1535/S/09 + + + +
1542/S/09 NWJ + + + +
1545/S/09 MEK + - +
1572/S/09 NWJ + + + +
1573/S/09 NWJ + + + +
1714/09 + + + +
1748 + + + +
2149/09 + + + +
2619/S/10 + + + +
Experimental procedure
One hundred fifty Ross 308 roosters, divided randomly into 5 equal, isolated groups (separate rooms - boxes), were used for the research. Chickens were fed with standard, complete feed produced by Agrocentrum Kolno, Poland and kept in conditions complying with recommendation of the biological material's manufacturer. Four-days-old chickens from boxes 1 , 2 and 3 were infected with Salmonella Enteritidis bacilli in a dose of lxl 05 CFU per animal (Table 8). Chickens from boxes 4 and 5 were not infected with Salmonella bacilli. The bacteriophage preparation was administered to chickens placed in boxes 1 (low concentration of 2.0 x 106 PFU/ml, marked as FN), 2 and 5 (high concentration of 2.0 x 108 PFU/ml, marked as Fw). The preparation was administered to roosters once a day for first 14 days of their lives. The bacteriophage agent was not administered to chickens from boxes 4 and 5. The rearing time was 21 days and during this period only five birds from different boxes died (Table 8). Since the detected death rate was minimal and did not depend on a given group of chickens therefore the death rate could not have been the result of the administration of the phage preparation.
Table 8. The scheme of administration of bacteria and bacteriophages, as well as birds' viability.
Box Salmonella infection Bacteriophage administration Chicken's viability
1 lxl05 CFU/bird 2.0 x 106 PFU/ml . 30/30
2 lxl05 CFU/bird 2.0 x 108 PFU/ml 29/30
3 lxl 05 CFU/bird - 28/30
4 - - 30/30
5 - 2.0 x 108 PFU/ml 28/30
Detection of Salmonella bacilli
Samples for Salmonella bacilli detection were collected according to the scheme described below (Figure 6):
• Investigation of feces during 21 days of experiment,
• Investigation of litter - sole smears were collected on 3rd, 15th and 21st day of birds' life,
• Investigation of liver, spleen and intestines of 21 -days-old broilers,
• Investigation of empty boxes before insertion of nestlings - smears were collected from walls, feeders, drinkers and floor (control),
• Investigation of one-day-old nestlings - internal organs, intestines and meconium (control).
Detection of Salmonella bacilli's presence in analyzed samples was carried out by an accredited laboratory -VETLAB (Brudzew, Poland). In 2008, this laboratory received authorization of the Chief Veterinary Officer (no. GIWhig-5120-23/08) to perform detection of Salmonella bacilli by means of bacteriological-qualitative method.
Salmonella bacilli were not detected in analyzed samples of internal organs and intestines of one-day-old nestlings, meconium, as well as smears from boxes before insertion of nestlings. The lack of Salmonella bacilli or different level of its detection in case of analysis of feces from 21 days of experiment, as well as sole smears analysis on 3rd, 15th and 21st day of life (Table 9), and internal organs analysis of 21 -days-old broilers (Figure 7) was dependent on the box under investigation. That is, as it was anticipated, no Salmonella bacilli were detected in chickens from boxes 4 and 5. In case of birds from box 3, which were infected with Salmonella bacilli and not treated with the bacteriophage preparation, the bacilli were detected starting from sixth day of life. Whereas, in case of chickens from boxes 1 and 2, which were infected with Salmonella bacilli and treated with the phage agent, inhibition of bacteria propagation was clearly seen until administration of the phage preparation was stopped. What is important, the number of bacilli detected in internal organs and intestines of 21 -days-old birds was very low in relation to chickens which were not treated with the phage preparation. Thus, bacteriophages prevent propagation of bacteria and consequently the appearance of bacteria in feces of birds infected during the experiment. Accordingly, it can be observed that bacteriophages decrease 200-fold the infection level even a week after discontinuation of phage treatment.
Table 9. Level of Salmonella bacilli's occurrence in feces during the experiment.
Salmonella bacilli occurrence
Phage
Day Infection Box 1 Box 2 Box 3 Box 4 Box 5
addition
FN+/S+ FW+/S+ F-/S+ F-/S- FW+/S-
1 - - - - Yes
2 - - - - Yes
3 2.5 x 103 - - - - Yes
4 - - - - Yes
5 - - - - Yes
6 - - 1.0 x 10' - Yes
7 - - + - Yes
8 - - 5.3 x 103 - Yes
9 - - + - Yes
10 - - 1.0 x 104 - Yes
1 1 - - + - Yes
12 - 3.0 x 101 3.5 x lO4 - -Yes
13 - - + - Yes
14 - 2.0 x 103 5.5 x 103 - Yes
15 4.1 x 103 1.0 x 102 1.5 x 103 - No
16 + + + - No
17 2.1 x 102 + 3.0 x 104 - No
21 5.0 x 102 2.2 x 103 4.3 x 104 - No "-" means, no Salmonella bacilli were detected
"+" means that Salmonella bacilli were detected, but it was difficult to determine their titer
Detection of bacteriophages ' occurrence.
Samples analyzed for bacteriophage presence were collected from feces during 21 days of the experiment and from smears from all boxes before introduction of nestlings, before infection and also a day and a week after discontinuation of phage treatment. No bacteriophages were detected in internal organs. It was observed that lack of bacteriophages or different level of their detection in birds' feces (Table 10) and sole smears analyses (Table 11) depended on the given box of chicken under analysis. That is, bacteriophages were detected in feces of chickens form boxes 1, 2 and 5, which were administered the phage agent. However, their number decreased after discontinuation of the treatment, and especially in case of birds from boxes 2 and 5, where high phage concentration was used, bacteriophages were no longer detected. It is worth adding that much smaller number of bacteriophages was detected in feces from box 5 compared to feces from box 2, which can be the result of impossibility of phage's propagation due to the lack of Salmonella bacilli.
Table 10. Bacteriophage's titer level in poultry feces.
Bacteriophage's titer
Day Box 1 Box 2 Box 3 Box 4 Box 5
FN+/S+ FW+/S+ F-/S+ F-/S- F+/S-
1 0 0 0 0 0
3 0 1.8 x 107 0 0 5.6 x 102
10 8.0 x 106 5.5 x 104 0 0 5.0 x 103
15 1.2 x 107 5.0 x 101 0 0 8.2 x 102
17 1.7 x 104 0 0 0 0
21 5.0 x 101 0 0 0 0
Table 11. Bacteriophage's titer level in sole smears under analysis.
Bacteriophage's titer
Day Box 1 Box 2 Box 3 Box 4 Box 5
FN+/S+ FW+/S+ F-/S+ F-/S- F+/S-
One day after discontinuation of
1.0 x 105 1.0 x 103 0 0 2.4 x 103 phage treatment (15)
One week after discontinuation
6.5 x 105 0 0 0 0 of phage treatment (21) Conclusions from the investigation of the effect of bacteriophage preparation on broilers
Based on the tests performed, one can conclude that the preparation is safe and efficient.
1. The preparation is safe for poultry.
2. Bacteriophages pass through the intestinal tract and reach the feces and litter.
3. Bacteriophages do not enter internal organs of the birds.
4. Bacteriophages disappear after discontinuation of administration of the preparation.
5. Bacteriophages prevent the appearance of bacteria in feces of experimentally infected birds.
6. Bacteriophages decrease 200-fold the infection level one week after discontinuation of the phage treatment.

Claims

Claims
1. The method of obtaining a strain of bacteriophage specific to a selected strain of bacteria, characterized in that: a) a collection of bacteriophage strains containing a strain of bacteriophage specific to a selected strain of bacteria is obtained,
b) culture of a selected strain of bacteria on a sterile culture medium is conducted, c) the culture samples are applied on the special multi-well measuring plate, then a suspension of tested bacteriophage strain at various concentrations is added and it is incubated at 37° C for at least 4 hours,
d) resazurin is added to the culture samples and incubation is continued in the dark at about 37° C for at least 3 hours, e) the colour or fluorescence of culture is being controlled, as well as bacteripohage strain contained in the culture that retains the blue colour or shows no significant increase in fluorescence compared with the control sample, is identified as a strain of bacteriophage specific to a selected strain of bacteria. A sterile sample that was treated with the same incubation is used as a control sample.
f) identified strain of bacteriophage specific to a selected strain of bacteria is propagated.
2. Method according to claim 1, characterized in that the selected bacterial strain is a strain of S. enterica serovar Enteritidis.
3. Application of bacteriophages in manufacturing of the preparation for preventing or fighting infections of farm animals, especially poultry, with pathogenic strains of bacteria sensitive to these phages, while the manufactured product is intended to be administered with food or water to vulnerable animals at intervals of one to seven days.
4. Method according to claim 3, characterized in that the manufactured preparation provides at least 200-fold reduction in the level of infection for a week after discontinuation of administration.
5. Method according to claim 3, characterized in that the infection to be fought is an infection of poultry with pathogenic strains of Salmonella sp, and in the preparation's manufacturing process, bacteriophage strain selected from the group consisting of: PCM F/00069 (strain 8 sent in 1748), PCM F/00070 (strain 8 sent 65 ) and PCM F/00071 (strain 3 sent 1) is used.
6. Bacteriophage strain suitable for the prevention or eradication of infection by pathogenic strains of Salmonella sp selected from the group consisting of: PCM F/00069 (strain 8 sent in 1748), PCM F/00070 (strain 8 sent 65) and PCM F/00071 (strain 3 sent 1 ) and exhibiting stability in refrigerated storage conditions for at least 3 months.
PCT/IB2012/054070 2011-08-25 2012-08-09 The method of obtaining a strain of bacteriofage, specific strains of bacteriophage and use thereof WO2013027146A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US14/240,195 US9476086B2 (en) 2011-08-25 2012-08-09 Bacteriophage with activity against pathogenic strains of Salmonella
RU2014111125/10A RU2573934C2 (en) 2011-08-25 2012-08-09 Method for obtaining bacteriophage strain, specific strains of bacteriophages and their application
EP12770231.4A EP2747578B1 (en) 2011-08-25 2012-08-09 The method of obtaining a strain of bacteriophage, specific strains of bacteriophage and use thereof
ES12770231T ES2710429T3 (en) 2011-08-25 2012-08-09 Method to obtain a strain of bacteriophage, specific strains of bacteriophage and use thereof
UAA201403018A UA112551C2 (en) 2011-08-25 2012-09-08 BACTERIOPHAGA STRAIN AND ITS APPLICATION
US15/297,587 US9999237B2 (en) 2011-08-25 2016-10-19 Method of inhibiting the growth of Salmonella

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PLPL396080 2011-08-25
PL396080A PL217019B1 (en) 2011-08-25 2011-08-25 Method for obtaining a strain of bacteriophage, specific bacteriophage strains and their use

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/240,195 A-371-Of-International US9476086B2 (en) 2011-08-25 2012-08-09 Bacteriophage with activity against pathogenic strains of Salmonella
US15/297,587 Division US9999237B2 (en) 2011-08-25 2016-10-19 Method of inhibiting the growth of Salmonella

Publications (1)

Publication Number Publication Date
WO2013027146A1 true WO2013027146A1 (en) 2013-02-28

Family

ID=47010653

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2012/054070 WO2013027146A1 (en) 2011-08-25 2012-08-09 The method of obtaining a strain of bacteriofage, specific strains of bacteriophage and use thereof

Country Status (10)

Country Link
US (2) US9476086B2 (en)
EP (1) EP2747578B1 (en)
ES (1) ES2710429T3 (en)
HU (1) HUE041484T2 (en)
PL (1) PL217019B1 (en)
PT (1) PT2747578T (en)
RU (1) RU2573934C2 (en)
TR (1) TR201819164T4 (en)
UA (1) UA112551C2 (en)
WO (1) WO2013027146A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160279070A1 (en) * 2013-10-28 2016-09-29 Proteon Pharmaceuticals S.A. Methods for encapsulation and microcapsules produced thereby
ITUA20162204A1 (en) * 2016-04-08 2017-10-08 Cosvitec Soc Cons A R L ISOLATION PROTOCOL AND USE OF BACTERIOPHAGES, SUCH AS AND IN COMBINATION WITH LATTOFERRINA, FOR THE PRODUCTION OF PRESIDENTS FOR THE CONSERVATION OF FOOD, THE SANIFICATION OF THE ENVIRONMENTS AND THE CARE OF GASTROENTERIC SYNDROMES FROM SALMONELLA SPP. IN MAN AND ANIMALS
CN108179197A (en) * 2018-01-09 2018-06-19 山东农业大学 Chicken ring RNA Chr9:10814512 | 10838667 genetic test primers, method and application
CN112725289A (en) * 2021-01-25 2021-04-30 南京悦联生物科技有限公司 Method for rapidly screening bacteriophage for treatment

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017089947A2 (en) 2015-11-25 2017-06-01 Universidad De Los Andes Composition comprising bacteriophages for reducing, eliminating and/or preventing salmonella enteritidis, salmonella typhimurium and salmonella paratyphi b
US20190271693A1 (en) * 2016-11-28 2019-09-05 Sonanutech Inc. Methods, compositions, and kits for detecting bacteriophage in a sample
US11224626B2 (en) * 2017-08-25 2022-01-18 The United States Of America As Represented By The Secretary Of The Navy Methods of identifying bacteriophages that can infect and kill host-adapted infectious pathogenic bacteria
FR3103198A1 (en) 2019-11-15 2021-05-21 Commissariat à l'Energie Atomique et aux Energies Alternatives Method for determining the sensitivity of a bacterial strain to a bacteriophage virus.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003054173A1 (en) * 2001-12-13 2003-07-03 Societe Des Produits Nestle S.A. Isolated phages and their use in food or pet food products
WO2003103578A2 (en) * 2002-06-05 2003-12-18 Iowa State University Research Foundation, Inc. Bacteriophage and enzymes lytic to salmonellae
US20110052544A1 (en) * 2009-09-03 2011-03-03 Cj Cheiljedang Corporation Novel bacteriophage and antibacterial composition comprising the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU543260A1 (en) 1975-07-25 1984-04-15 Всесоюзный Ордена Трудового Красного Знамени Научно-Исследовательский Противочумный Институт "Микроб" Method for preparing cholera bacteriophages for differentiating el-tor vibrios into virulent and avirulent
DE19517940A1 (en) 1995-05-18 1996-11-21 Merck Patent Gmbh Detection of listeria using recombinant bacteriophages
WO2001000786A2 (en) 1999-06-25 2001-01-04 Spring Diagnostics Ltd. Bacteriophage library useful for typing bacteria and system and method utilizing same
RU2412243C1 (en) * 2009-06-16 2011-02-20 Федеральное государственное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФГУН ГНЦ ВБ "Вектор" Роспотребнадзора) Strain of salmonella typhimurium bacteriophage s-394, possessing lytic activity
US20110052541A1 (en) * 2009-09-03 2011-03-03 Cj Cheiljedang Corporation Novel bacteriophage and antibacterial composition comprising the same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003054173A1 (en) * 2001-12-13 2003-07-03 Societe Des Produits Nestle S.A. Isolated phages and their use in food or pet food products
WO2003103578A2 (en) * 2002-06-05 2003-12-18 Iowa State University Research Foundation, Inc. Bacteriophage and enzymes lytic to salmonellae
US20110052544A1 (en) * 2009-09-03 2011-03-03 Cj Cheiljedang Corporation Novel bacteriophage and antibacterial composition comprising the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DOOLEY E S: "Rapid visualization of the results of staphylococcal bacteriophage typing", MILITARY MEDICINE, ASSOCIATION OF MILITARY SURGEONS OF THE US, BETHESDA, MD, US, vol. 121, no. 5, 1 January 1962 (1962-01-01), pages 399 - 404, XP009165683, ISSN: 0026-4075 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160279070A1 (en) * 2013-10-28 2016-09-29 Proteon Pharmaceuticals S.A. Methods for encapsulation and microcapsules produced thereby
US10478401B2 (en) * 2013-10-28 2019-11-19 Proteon Pharmaceuticals S.A. Methods for encapsulation and microcapsules produced thereby
ITUA20162204A1 (en) * 2016-04-08 2017-10-08 Cosvitec Soc Cons A R L ISOLATION PROTOCOL AND USE OF BACTERIOPHAGES, SUCH AS AND IN COMBINATION WITH LATTOFERRINA, FOR THE PRODUCTION OF PRESIDENTS FOR THE CONSERVATION OF FOOD, THE SANIFICATION OF THE ENVIRONMENTS AND THE CARE OF GASTROENTERIC SYNDROMES FROM SALMONELLA SPP. IN MAN AND ANIMALS
CN108179197A (en) * 2018-01-09 2018-06-19 山东农业大学 Chicken ring RNA Chr9:10814512 | 10838667 genetic test primers, method and application
CN108179197B (en) * 2018-01-09 2021-11-30 山东农业大学 Chicken ring RNA Chr9:10814512|10838667 gene detection primer, method and application
CN112725289A (en) * 2021-01-25 2021-04-30 南京悦联生物科技有限公司 Method for rapidly screening bacteriophage for treatment

Also Published As

Publication number Publication date
PL396080A1 (en) 2013-03-04
EP2747578B1 (en) 2018-09-12
ES2710429T3 (en) 2019-04-25
PT2747578T (en) 2019-01-21
UA112551C2 (en) 2016-09-26
PL217019B1 (en) 2014-06-30
HUE041484T2 (en) 2019-05-28
RU2573934C2 (en) 2016-01-27
EP2747578A1 (en) 2014-07-02
US20140220659A1 (en) 2014-08-07
TR201819164T4 (en) 2019-03-21
US9476086B2 (en) 2016-10-25
US20170035077A1 (en) 2017-02-09
US9999237B2 (en) 2018-06-19
RU2014111125A (en) 2015-09-27

Similar Documents

Publication Publication Date Title
US9999237B2 (en) Method of inhibiting the growth of Salmonella
Nabil et al. Assessing the impact of bacteriophages in the treatment of Salmonella in broiler chickens
BR112020013712A2 (en) anhydrous compositions comprising a co-selected microbiota, method of use and medicine
Zhou et al. Antibiotic administration routes and oral exposure to antibiotic resistant bacteria as key drivers for gut microbiota disruption and resistome in poultry
Rahaman et al. Poultry Salmonella specific bacteriophage isolation and characterization.
Kowalska et al. Anti-salmonella potential of new strains with the application in the poultry industry
Al‐Tarazi et al. Effect of dietary formic and propionic acids on Salmonella pullorum shedding and mortality in layer chicks after experimental infection
Tang et al. Antimicrobial resistance surveillance of Escherichia coli from chickens in the Qinghai Plateau of China
WO2015188230A1 (en) Bacteriophage production method
Barrera et al. Changes in dominant Escherichia coli and antimicrobial resistance after 24 hr in fecal matter
CN114717199A (en) Salmonella phage CKT1 without drug resistance gene transduction ability and application thereof
Titécat et al. Safety and efficacy of an AIEC-targeted bacteriophage cocktail in a mice colitis model
CN117050954B (en) Broad-spectrum salmonella phage vB-SenS-S1 and composition containing phage
Zhao et al. Probiotic characteristics and whole-genome sequence analysis of Pediococcus acidilactici isolated from the feces of adult beagles
CN115029323B (en) Drug-resistant staphylococcus aureus phage SP160 and application thereof in preparation of bacteriostat
CN113444695B (en) Escherichia coli bacteriophage with high fermentation efficiency and good clinical effect and application thereof
CN115948348A (en) Wide-spectrum avian salmonella bacteriophage and application and composition thereof
Han et al. Characteristics of a novel temperate bacteriophage against Staphylococcus arlettae (vB_SarS_BM31)
TWI729523B (en) Bacillus amyloliquefaciens and use of the bacillus amyloliquefaciens for manufacturing compositions to inhibit or kill pathogenic bacteria and its metabolites for manufacturing compositions to inhibit or kill pathogenic bacteria
CN110129282B (en) Vibrio alginolyticus bacteriophage, bacteriophage composition and application thereof
Renfert et al. The use of a salmonella bacteriophage in bearded dragons: Application, passage time and reisolation
Osborne et al. Exploring the potential of algae-bacteria interactions in the biocontrol of the marine pathogen Vibrio parahaemolyticus
Strand Analyses of bacteriophages to Yersinia ruckeri and the salmon (Salmo salar L.) antibody response to the bacteriophages.
Esmaeil Zadeh et al. Evaluation of Specific Bacteriophage Against Salmonella infantis and Its Antibacterial Effects Compared to Ciprofloxacin in In Vitro Conditions
CN110923210B (en) Method for preventing and controlling hatching field stinky eggs by utilizing bacteriophage

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12770231

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 14240195

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2014111125

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A201403018

Country of ref document: UA